RocRock Bio's project on "CAR-M Therapy for Recurrent and Refractory Ovarian Cancer" has successfully passed the ethical review by the Affiliated Hospital of Xuzhou Medical University and received approval for investigator-initiated clinical trials (IIT). This milestone signifies the official entry of RocRock Bio's CAR-M pipeline into the clinical research phase. RocRock Bio has been committed to innovating and translating CAR-M cell therapy into clinical applications, leveraging its safe and mature technology platform to develop cell-based drugs for solid tumors like ovarian cancer and glioblastoma. The Affiliated Hospital of Xuzhou Medical University, RocRock Bio's partner, possesses extensive clinical experience and technical expertise in immune cell therapy. RocRock Bio also extends sincere gratitude to Jiangsu Jicai Juchuang Bio-technology Research Institute Co., Ltd. for its organizational and coordinative efforts during the ethical review process of the clinical research project.
RocRock Bio, incubated in Berlin and established in Shenzhen in April 2021, has developed a tripartite layout with centers in Shenzhen, Suzhou, and Berlin. Led by Chinese scientists returned from Europe and supported by a global team of experts, RocRock Bio leverages over a decade of cutting-edge research to focus on macrophage-based immunotherapy. The company is advancing the R&D and industrialization of CAR-M technology, aiming to establish a global leading closed-loop industry chain. This strategic move positions Chinese enterprises at the forefront of global macrophage-based solid tumor treatment, making significant contributions to the field of biomedicine.
Xuzhou Medical University Affiliated Hospital boasts a national Phase I Clinical Research Center. Its Clinical Trial Ethics Committee obtained SIDCER-FERCAP international ethics certification in 2015, ranking its ethics review technology and management among the nation's most advanced. It is the only ethics committee in the Huaihai Economic Zone to have passed FERCAP certification. The hospital has initiated over 50 CAR-T immunotherapy clinical trials and stands as one of the leading hospitals in the country for CAR-T clinical trials.
Relying on Xuzhou Medical University and the Jiangsu Institute of Tumor Biotherapy, Jiangsu Jicui Rising Innovation Biotech Co., Ltd. Research Institute Co., Ltd. is the only cell-therapy-drug-focused research institute in the Yangtze River Delta region. It aims to build a first-class domestic tumor biotherapy technology platform integrating R & D, transformation, and clinical application. With over 20 years of research and industrial experience in cell therapy and a mature R & D and clinical transformation team, the company has developed multiple fully human CAR-T cell pipelines and initiated several IIT clinical studies.
Free AI Website Software